DUBLIN, Ireland — Perrigo Co. and Allergan plc have rolled out guaifenesin 1,200-mg and dextromethorphan HBr 60-mg extended-release tablets, a combination expectorant and cough suppressant. The companies said Tuesday that the product marks the first over-the-counter store-brand equivalent to Mucinex DM 1,200-mg ER tablets from Reckitt Benckiser (RB) for retail and wholesale customers. First shipments
DUBLIN, Ireland — Allergan plc has received final approval from the Food and Drug Administration for rosuvastatin calcium tablets, a cholesterol-lowering medication. The company said its rosuvastatin calcium product comes in dosages of 5 mg, 10 mg, 20 mg and 40 mg and is a generic version of Crestor tablets from AstraZeneca. Allergan noted that
NEW YORK — Pfizer Inc. and Allergan PLC have, by mutual agreement, terminated their planned merger. Pfizer management attributed the decision to new tax rules issued by the Treasury Department that are specifically intended to make such combinations less attractive. Under the proposed merger, Pfizer would have shifted its corporate address — but not its
DUBLIN, Ireland — Perrigo Co. plc and Allergan plc have begun shipping 1,200-mg guaifenesin extended-release tablets, an expectorant, to retail and wholesale customers. The companies said this week that the over-the-counter product, a generic equivalent to Reckitt Benckiser’s Mucinex ER tablets (guaifenesin 1,200 mg), is packaged and marketed as store brands or retailer own-label brands. “This
NEW YORK — Pfizer Inc. has announced the executive leadership team following the completion of its acquisition of Allergan plc. The pharmaceutical giant said Monday that, as announced previously, Allergan chief executive officer Brent Saunders will become president and chief operating officer of the merged company, overseeing Pfizer and Allergan’s combined commercial businesses, manufacturing and
DUBLIN, Ireland — Allergan plc and Perrigo Co. plc have launched combination guaifenesin 600-mg and pseudoephedrine HCl 60-mg extended-release tablets to retail and wholesale customers. Allergan and Perrigo said Monday that the initial shipments of the new store-brand product, which began in December, mark a first-to-market achievement for the companies. “This first-to-market launch illustrates the
DUBLIN, Ireland — Allergan plc has released Viberzi (eluxadoline), a treatment for irritable bowel syndrome with diarrhea (IBS-D), to U.S. pharmacies. The company said Monday that Viberzi, a twice-daily oral medication, relieves the core symptoms of IBS-D: recurrent diarrhea and abdominal pain. Symptom relief was maintained throughout treatment in two pivotal clinical trials. “We are excited about the launch of Viberzi, which
NEW YORK — Despite widespread criticism over the issue of tax inversions, legal experts say that current regulatory restrictions in the United States are unlikely to block the $160 billion merger deal announced by U.S. pharmaceutical giant Pfizer and Ireland-based drug manufacturer Allergan Inc. Generally, tax inversions involve a U.S. firm reincorporating in a low-tax
NEW YORK and DUBLIN, Ireland — Pfizer Inc. plans to acquire Allergan Inc. for about $160 billion in the biggest deal ever in the health care sector. Pfizer said Monday that the transaction will allow the New York-based drug giant to relocate to Ireland to cut its U.S. tax burden. “The proposed combination of Pfizer
NEW YORK — Allergan plc and Pfizer Inc. have confirmed they’re exploring a possible combination. Dublin, Ireland-based Allergan released a statement Thursday saying it’s in early talks with Pfizer about a possible deal, and Pfizer later affirmed Allergan’s statement. No other details were disclosed by the two pharmaceutical companies — a merger of which would
JERUSALEM — Teva Pharmaceutical Industries Ltd. plans to buy Allergan’s generic drug business for about $40.5 billion and, with the deal, has withdrawn its proposal to acquire Mylan N.V. for approximately $40 billion. Teva said Monday that Dublin, Ireland-based Allergan will receive $33.75 billion in cash and $6.75 billion in shares of Teva. The agreement
